[REVISION HISTORY]
Intuitive Surgical corporate governance and financial status
2 recorded revisions of this situation.
What changed
2026-09-29 07:23 UTC → 2026-10-22 11:31 UTC ·
added
removed
Intuitive Surgical has undergone recent corporate governance updates and experienced fluctuations in its financial performance and stock valuation. In July 2026, the company implemented changes to its corporate bylaws regarding shareholder nomination rules, voting standards, and special general meeting conditions. During this period, Director Amy Ladd executed a pre-arranged Rule 10b5-1 trading plan to sell 72 shares of stock. While the company reported strong quarterly earnings—including a revenue increase of approximately 18.4 to 19 percent driven by a rise in worldwide procedures using da Vinci and Ion systems—its stock price faced downward pressure. By early September 2026, shares fell below $370, closing at $366.70 on the Nasdaq. This level was approximately 21.98 percent lower than the previous year’s price and significantly below the average analyst price target of approximately $508.68, despite reported adjusted earnings per share of $2.80. By late September 2026, shares rose 2.30 percent to $414.50. This recovery followed the release of a meta-analysis regarding the da Vinci platform, which examined over 14 million procedures. The study indicated that da Vinci procedures were associated with a “54 percent lower probability of conversion to open surgery” and approximately four hours shorter hospital stays compared to laparoscopic methods. Financial data from Q2 2026 showed In October 2026, the company reported third-quarter revenue of $2.89 $3.05 billion, exceeding analyst estimates of $2.91 billion, with recurring revenue accounting for 85 adjusted profit reaching $3 per diluted share. System sales rose 30 percent of to $769 million, supported by the total. While international placement of 546 da Vinci procedures increased by 20 percent, U.S. growth for the system slowed to 12 percent. Long-term growth is expected to be driven by robots, including 315 units of the new da Vinci 5 system upgrade cycle and generation. However, the expansion company tightened its 2026 forecast for worldwide da Vinci procedure growth to a midpoint of 14% to 15%. To broaden access, Intuitive plans to roll out an Extended Use Program in the Ion platform. US, pending regulatory approval.
Versions
- 2026-10-22 11:31 UTC Intuitive Surgical corporate governance and financial status
- 2026-09-29 07:23 UTC Intuitive Surgical corporate governance and financial status
- 2026-09-09 11:13 UTC Intuitive Surgical corporate governance and financial status
Select a version to see what changed compared to the one before it.